CHINA BOTON (03318.HK): RMB 160 Million Injection for 49% Stake in Shandong Ganghong, Booked as Associate
NewTimeSpace News: On 13 November 2026, CHINA BOTON (03318.HK) announced that its indirect wholly-owned subsidiary Shenzhen Boton Flavors & Fragrances Co., Ltd. entered into a capital injection agreement with the Target Company, Shandong Ganghong Biotechnology Co., Ltd., and the Target Shareholders, under which Shenzhen Boton conditionally agreed to inject RMB 160,000,000 (equivalent to about HKD 186,212,800) to acquire a 49% equity interest.
Of the consideration, RMB 4,803,922 (about HKD 5,590,949) will be injected into the Target Company as registered capital and the remaining RMB 155,196,078 (about HKD 180,621,851) will be credited to capital reserve. The Target Company's registered capital is currently RMB 5,000,000 and will become RMB 9,803,922 after the injection. On completion, the Target Shareholders, Wei Jie and Song Chuanlan, will hold 51% in aggregate and Shenzhen Boton will hold 49%, and the Target Company will be accounted for as an associate of the Company, with its results not consolidated into the Group's financial statements.
Under the agreement, the Target Shareholders jointly and severally guarantee that the Target Company's net profit for each of the 2027 and 2028 financial years will be no less than RMB 22,000,000, and no less than RMB 44,000,000 in aggregate over the two years. If actual net profit falls short, the Target Shareholders must pay cash compensation calculated at 49%. The consideration will be funded from internal resources in three instalments of RMB 32,000,000, RMB 64,000,000 and RMB 64,000,000, with completion required within 60 days of the first payment and no later than 8 January 2027.
An independent valuer used a price-earnings approach to value the 49% interest in the Target Group at about RMB 161,058,000 (equivalent to about HKD 187,444,132) as at 31 August 2026, applying an 18.78 times forward price-earnings multiple and a 20.43% discount for lack of marketability. The Target Group is engaged in the research, development, production and sale of pharmaceutical, pesticide and veterinary API intermediates, aroma products and other fine chemicals; it recorded an after-tax loss of about RMB 4,638 thousand in 2025 and after-tax profit of about RMB 4,308 thousand in 2024, with consolidated net assets of about RMB 16,990,000 as at 31 December 2025.
The board said the injection secures a stable upstream supply of key chemical intermediates and, with the Target Group's research capabilities, CNAS-accredited analytical centre and microchannel reaction technology, can optimise fragrance production processes, improve pilot-scale efficiency and open up pharmaceutical and agrochemical customers in North and East China. As one or more applicable percentage ratios exceed 5% but are below 25%, the injection constitutes a discloseable transaction exempt from shareholder approval.
- Fullgoal Hang Seng HK High Dividend ETF (03031.HK) Down 1.54% as Hong Kong Stocks Slide
- PINESTONE (00804.HK): Appoints Wu Yuanzheng as AI Business GM
- ALPHA PRO HLDGS (00948.HK): Clarifies 56.62M Excess Rights Shares
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND